ACE and COVID-19: In a study by Fosbøl et al. [48] users of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers more often died or developed severe COVID-19 compared to non-users (31.9% vs 14.2%), however, this difference was not significant when adjusting for age, sex and medical history (adjusted hazard ratio 1.04, 95% CI: 0.89–1.23).